Enhancing its cancer treatment domain, Oncology Pharma Inc (OTCMKTS: ONPH) plans to apply for patents for its licensed products. Aiming to create new IP, the company will initiate the plan with NanoSmart, Regen Biopharma, Sybleu, and Ribera Solutions. Not only is the company looking to expand the existing products, but it has also already started preliminary discussions with its aides to reach the goal.
As per reports, the company will utilize Clinical Research Organization services along with its existing research database to save time and expense in achieving patent opportunities. The announcement will help spearhead the company amongst the top in cancer treatment and achieve internal growth.
Earlier, a company spokesperson had revealed that they aimed to form strategic alliances to develop licensed agents and look for sources for their project financing. The company also wants to spearhead advanced clinical trials for its licensed products.
Meanwhile, the company has collaborated with Ribera Solutions to release a white paper for enhancing the patient engagement and retention portfolio. The platform called Connect2Med will help in aiding global studies and clinical findings for patients and healthcare providers. Connect2Med aims at building an online community of leads and databases for all stakeholders to provide a classified and safe place for helping in clinical trials. Using simple communication systems, this platform allows users to access patient database and can be easily integrated with CRM, HER, and CTMS programs. It will make the patient database easily accessible for any cancer-related clinical trials. It will also address dropouts from trials resulting in better results and higher efficacy of research.
It is looking forward to making cancer drug delivery effortless and faster, hastening the regulatory processes, developing new anti-cancer mechanisms with lesser toxins, and making the technology efficient for cancer specialists and patients. Earlier this year, the company initiated the development of SMD (Small Molecule Drug) to treat colon cancer.
 Plans to Patent its Licensed Products){kind=link}